Alvotech has successfully completed a second round of its US$ 100 million private placement, for US$ 35 million. The first round which was completed in October 2020, amounted to US$ 65 million. As part of the first round Shinhan from Korea, Baxter Healthcare SA from the US and ATHOS (Strüngmann

Cipla Gulf and Alvotech today announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of leading

Fuji Pharma will exclusively commercialize the medicines in Japan – discussions between the parties continue over additional biosimilar candidates Alvotech and Japanese pharmaceutical company Fuji Pharma (Tokyo Stock Exchange: 4554) announce that they have agreed on an extension on their exclusive

Through this partnership, a powerhouse has been created in one of the world’s largest biologics markets, designed to improve patient access to high quality biosimilars in China° Biosimilar candidates will be manufactured in a new Chinese biologic facility in Changchun Alvotech hf.

Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms AVT02 is highly similar to its reference product in terms of structure and function The pharmacokinetic (PK) similarity study for AVT02 (AVT02-GL-101) has met its primary

Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets such as South Africa.

Alvotech announced today that its parent company, Alvotech Holdings SA, has successfully completed a $65 million private placement round. This has resulted in the company issuing new shares to a group of new investors and existing shareholders, which will further finance the development and release

Alvotech and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets. The initial pipeline contains biosimilar candidates addressing

Alvotech and Teva bring together highly complementary capabilities to secure a leading position in the U.S. biosimilar market The collaboration is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines

Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms The Phase 1 PK similarity study for AVT02 (AVT02-GL-101) has met its primary objectives The Phase 3 confirmatory efficacy and safety study for AVT02 (AVT02-GL-301) has met